CoChat
Sign Up
Cited by 187SARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections Studiesvaccines and immunoinformatics approaches

The DOI matches its Crossref record; 116 of the 116 references it cites were found in a registry or an index.

Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines

Open access
Walls, Alexandra C., Miranda, Marcos C., Schäfer, Alexandra, Pham, Minh N., Greaney, Allison, Arunachalam, Prabhu S., Navarro, Mary-Jane, Tortorici, M. Alejandra, Rogers, Kenneth, O’Connor, Megan A., Shirreff, Lisa, Ferrell, Douglas E., Bowen, John, Brunette, Natalie, Kepl, Elizabeth, Zepeda, Samantha K., Starr, Tyler, Hsieh, Ching-Lin, Fiala, Brooke, Wrenn, Samuel, Pettie, Deleah, Sydeman, Claire, Sprouse, Kaitlin R., Johnson, Max, Blackstone, Alyssa, Ravichandran, Rashmi, Ogohara, Cassandra, Carter, Lauren, Tilles, Sasha W., Rappuoli, Rino, Leist, Sarah R., Martinez, David R., Clark, Matthew, Tisch, Roland, O’Hagan, Derek T., Van Der Most, Robbert, Van Voorhis, Wesley C., Corti, Davide, McLellan, Jason S., Kleanthous, Harry, Sheahan, Timothy P., Smith, Kelly D., Fuller, Deborah H., Villinger, Francois, Bloom, Jesse, Pulendran, Bali, Baric, Ralph S., King, Neil P., Veesler, David·2021·Cell
DOI 10.1016/j.cell.2021.09.015PMC PMC7986998

Published version of a preprint

Open this paper in CoChat — free accountOpen PDF

Abstract

Understanding the ability of SARS-CoV-2 vaccine-elicited antibodies to neutralize and protect against emerging variants of concern and other sarbecoviruses is key for guiding vaccine development decisions and public health policies. We show that a clinical stage multivalent SARS-CoV-2 receptor-binding domain nanoparticle vaccine (SARS-CoV-2 RBD-NP) protects mice from SARS-CoV-2-induced disease after a single shot, indicating that the vaccine could allow dose-sparing. SARS-CoV-2 RBD-NP elicits high antibody titers in two non-human primate (NHP) models against multiple distinct RBD antigenic sites known to be recognized by neutralizing antibodies. We benchmarked NHP serum neutralizing activity elicited by RBD-NP against a lead prefusion-stabilized SARS-CoV-2 spike immunogen using a panel of single-residue spike mutants detected in clinical isolates as well as the B.1.1.7 and B.1.351 variants of concern. Polyclonal antibodies elicited by both vaccines are resilient to most RBD mutations tested, but the E484K substitution has similar negative consequences for neutralization, and exhibit modest but comparable neutralization breadth against distantly related sarbecoviruses. We demonstrate that mosaic and cocktail sarbecovirus RBD-NPs elicit broad sarbecovirus neutralizing activity, including against the SARS-CoV-2 B.1.351 variant, and protect mice against severe SARS-CoV challenge even in the absence of the SARS-CoV RBD in the vaccine. This study provides proof of principle that sarbecovirus RBD-NPs induce heterotypic protection and enables advancement of broadly protective sarbecovirus vaccines to the clinic.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.cell.2021.09.015

Cites

116 of 116 references verified0 citation errors · 0 not checkable

Statistics

Figures

Extended Data Fig. 1: SARS-CoV-2 S 2P binding titers elicited by RBD-NP vaccination in mice. Antigen-specific Abs were measured 2 (a) or 5 (b) weeks post-prime; teal squares: 2×0.1 μg group; filled teal circles: 2×1 μg group; open teal circles: 1×1 μg group.
Extended Data Fig. 1: SARS-CoV-2 S 2P binding titers elicited by RBD-NP vaccination in mice. Antigen-specific Abs were measured 2 (a) or 5 (b) weeks post-prime; teal squares: 2×0.1 μg group; filled teal circles: 2×1 μg group; open teal circles: 1×1 μg group.CC BY-NC-ND · PubMed Central
Extended Data Fig. 2: Effects of mutations on binding of HCP antibodies to RBD and FACS gating strategy. (a) Correlation plots of site- and mutation-level escape for each of the two independent RBD mutant libraries for the Ab-escape map shown in Fig. 2b. Site-level escape is the sum of the escape fractions for each mutation at a site. (b) Hierarchical FACS gating strategy used for selecting yeast cells expressing antibody-escape RBD variants. First, gates are selected to enrich for single cells (SSC-A vs. FSC-A, and FSC-W vs. FSC-H) that also express RBD (FITC-A vs. FSC-A, cells in pink). Second, cells expressing RBD mutants with reduced polyclonal Ab binding, detected with an anti-IgA+IgG+IgM secondary Ab, were selected with a gate that captured the ~5% of cells with the lowest Ab binding (cells in blue).
Extended Data Fig. 2: Effects of mutations on binding of HCP antibodies to RBD and FACS gating strategy. (a) Correlation plots of site- and mutation-level escape for each of the two independent RBD mutant libraries for the Ab-escape map shown in Fig. 2b. Site-level escape is the sum of the escape fractions for each mutation at a site. (b) Hierarchical FACS gating strategy used for selecting yeast cells expressing antibody-escape RBD variants. First, gates are selected to enrich for single cells (SSC-A vs. FSC-A, and FSC-W vs. FSC-H) that also express RBD (FITC-A vs. FSC-A, cells in pink). Second, cells expressing RBD mutants with reduced polyclonal Ab binding, detected with an anti-IgA+IgG+IgM secondary Ab, were selected with a gate that captured the ~5% of cells with the lowest Ab binding (cells in blue).CC BY-NC-ND · PubMed Central
Extended Data Fig. 3. Evaluation of vaccine-elicited binding and neutralizing Ab titers against SARS-CoV-2 variants and distinct sarbecoviruses. (a) Wildtype (closed circles) and B.1.351 (open circles) SARS-CoV-2 RBD-specific Ab binding titers of SARS-CoV-2 RBD-NP-elicited sera in pigtail macaques (magenta) and in rhesus macaques (blue), HexaPro-elicited sera (gray), or HCP (orange) analyzed by ELISA. (b) Neutralizing Ab titers against wildtype (D614G) SARS-CoV-2 S, B.1.1.7, and B.1.351 S HIV pseudoviruses from NHPs immunized with 12GS-RBD-NP at day 56 (two immunizations, filled symbols) and 196 (three immunizations, open symbols) (c) Cladogram based on sarbecovirus RBD amino acid sequences. (d) Biolayer interferometry analysis of binding of 1 μM purified polyclonal pigtail macaque IgGs (obtained 70 days post prime) to sarbecovirus RBDs immobilized at the surface of biosensors. (e) SARS-CoV-2 S 2P (circles) or SARS-CoV S 2P (squares) Ab binding titers of SARS-CoV-2 RBD-NP-elicited sera in Pigtail macaques (magenta) or HexaPro-elicited sera in Rhesus macaques (gray) analyzed by ELISA. (f) Competition ELISA between 0.13 nM human ACE2-Fc and RBD-NP-elicited sera in pigtail macaques, rhesus macaques, or HexaPro S-elicited sera in rhesus macaques against SARS-CoV S 2P at various time points following vaccination benchmarked against COVID-19 HCP. Each plot shows the magnitude of inhibition of ACE2 binding to immobilized SARS-CoV S 2P, expressed as reciprocal serum dilution blocking 50% of the maximum binding response.
Extended Data Fig. 3. Evaluation of vaccine-elicited binding and neutralizing Ab titers against SARS-CoV-2 variants and distinct sarbecoviruses. (a) Wildtype (closed circles) and B.1.351 (open circles) SARS-CoV-2 RBD-specific Ab binding titers of SARS-CoV-2 RBD-NP-elicited sera in pigtail macaques (magenta) and in rhesus macaques (blue), HexaPro-elicited sera (gray), or HCP (orange) analyzed by ELISA. (b) Neutralizing Ab titers against wildtype (D614G) SARS-CoV-2 S, B.1.1.7, and B.1.351 S HIV pseudoviruses from NHPs immunized with 12GS-RBD-NP at day 56 (two immunizations, filled symbols) and 196 (three immunizations, open symbols) (c) Cladogram based on sarbecovirus RBD amino acid sequences. (d) Biolayer interferometry analysis of binding of 1 μM purified polyclonal pigtail macaque IgGs (obtained 70 days post prime) to sarbecovirus RBDs immobilized at the surface of biosensors. (e) SARS-CoV-2 S 2P (circles) or SARS-CoV S 2P (squares) Ab binding titers of SARS-CoV-2 RBD-NP-elicited sera in Pigtail macaques (magenta) or HexaPro-elicited sera in Rhesus macaques (gray) analyzed by ELISA. (f) Competition ELISA between 0.13 nM human ACE2-Fc and RBD-NP-elicited sera in pigtail macaques, rhesus macaques, or HexaPro S-elicited sera in rhesus macaques against SARS-CoV S 2P at various time points following vaccination benchmarked against COVID-19 HCP. Each plot shows the magnitude of inhibition of ACE2 binding to immobilized SARS-CoV S 2P, expressed as reciprocal serum dilution blocking 50% of the maximum binding response.CC BY-NC-ND · PubMed Central
Extended Data Fig. 4: In vitro characterization of sarbecovirus RBD-NP immunogens. a, Designed models of the various vaccine candidates evaluated. Scale bars, 36 nm. b, SDS-PAGE analysis of purified nanoparticles. DTT, dithiothreitol; F/T, post-freeze/thaw. c, Dynamic light scattering. d, Electron micrographs of negatively stained samples. Scale bars, 50 nm. e, Binding of 100 nM SEC-purified nanoparticle immunogens and the non-assembling cocktail immunogen (which was not purified with SEC) to immobilized hACE2-Fc. f, SEC chromatogram overlay of purified RBD-NP and non-assembling cocktail.
Extended Data Fig. 4: In vitro characterization of sarbecovirus RBD-NP immunogens. a, Designed models of the various vaccine candidates evaluated. Scale bars, 36 nm. b, SDS-PAGE analysis of purified nanoparticles. DTT, dithiothreitol; F/T, post-freeze/thaw. c, Dynamic light scattering. d, Electron micrographs of negatively stained samples. Scale bars, 50 nm. e, Binding of 100 nM SEC-purified nanoparticle immunogens and the non-assembling cocktail immunogen (which was not purified with SEC) to immobilized hACE2-Fc. f, SEC chromatogram overlay of purified RBD-NP and non-assembling cocktail.CC BY-NC-ND · PubMed Central
Extended Data Fig. 5: Accelerated stability studies of nanoparticle immunogens. The physical and antigenic stability of mRBD-NP, cRBD-NP, and (SARS-CoV-2) RBD-NP samples incubated at four different temperatures was followed for four weeks. a, The ratio of UV/vis absorbance at 320 nm/280 nm is a measure of turbidity. b, Hydrodynamic diameter of the nanoparticles measured using dynamic light scattering. c, hACE2 binding, measured by comparing the peak amplitude of hACE2 binding for each sample to a reference sample stored at <−70°C using biolayer interferometry. d, Electron micrographs of negatively stained samples after incubation for 28 days at the indicated temperatures. Scale bar, 50 nm.
Extended Data Fig. 5: Accelerated stability studies of nanoparticle immunogens. The physical and antigenic stability of mRBD-NP, cRBD-NP, and (SARS-CoV-2) RBD-NP samples incubated at four different temperatures was followed for four weeks. a, The ratio of UV/vis absorbance at 320 nm/280 nm is a measure of turbidity. b, Hydrodynamic diameter of the nanoparticles measured using dynamic light scattering. c, hACE2 binding, measured by comparing the peak amplitude of hACE2 binding for each sample to a reference sample stored at <−70°C using biolayer interferometry. d, Electron micrographs of negatively stained samples after incubation for 28 days at the indicated temperatures. Scale bar, 50 nm.CC BY-NC-ND · PubMed Central
Extended Data Fig. 6 Confirmation of co-display using sandwich biolayer interferometry. a, The SARS-CoV-2 S-specific mAb S2H14 immobilized on protein A biosensors was used to capture various nanoparticle immunogens. The captured nanoparticles were subsequently exposed to a Fab derived from the SARS-CoV S-specific mAb S230. b, hACE2-Fc immobilized on protein A biosensors was used to capture various nanoparticle immunogens. The captured nanoparticles were subsequently exposed to a Fab derived from the SARS-CoV S-specific mAb S230.
Extended Data Fig. 6 Confirmation of co-display using sandwich biolayer interferometry. a, The SARS-CoV-2 S-specific mAb S2H14 immobilized on protein A biosensors was used to capture various nanoparticle immunogens. The captured nanoparticles were subsequently exposed to a Fab derived from the SARS-CoV S-specific mAb S230. b, hACE2-Fc immobilized on protein A biosensors was used to capture various nanoparticle immunogens. The captured nanoparticles were subsequently exposed to a Fab derived from the SARS-CoV S-specific mAb S230.CC BY-NC-ND · PubMed Central
Extended Data Fig 7: Serum Ab binding titers elicited by mosaic and cocktail RBD-NPs. (a) ELISA binding to SARS-CoV-2 S at week 5. (b–d) Titers of SARS-CoV-2 S-specific (b) ACE2-Fc (c) CR3022 (d) and S309 competing antibodies in immunized mouse sera. (e) ELISA binding to SARS-CoV S at week 5. (f–i) ELISA binding to RBDs from the (f) SARS-CoV-2 (g) SARS-CoV (h) WIV1 (i) RaTG13 spikes.
Extended Data Fig 7: Serum Ab binding titers elicited by mosaic and cocktail RBD-NPs. (a) ELISA binding to SARS-CoV-2 S at week 5. (b–d) Titers of SARS-CoV-2 S-specific (b) ACE2-Fc (c) CR3022 (d) and S309 competing antibodies in immunized mouse sera. (e) ELISA binding to SARS-CoV S at week 5. (f–i) ELISA binding to RBDs from the (f) SARS-CoV-2 (g) SARS-CoV (h) WIV1 (i) RaTG13 spikes.CC BY-NC-ND · PubMed Central
Figure 1. A single immunization with RBD-NP protects Balb/c cByJ mice from SARS-CoV-2 MA10 challenge. (a–b) Serum neutralizing Ab titers at 2 (a) or 5 (b) weeks post-prime determined using an MLV pseudotyping system; teal squares: 2×0.1 μg group; filled teal circles: 2×1 μg group; open teal circles: 1×1 μg group. (c) Weight loss following SARS-CoV-2 MA10 challenge up to 4 days post infection (N=6). Black, naïve mice; filled teal circles, 2×1 μg group; open teal circles, 1×1 μg group. (d) Congestion score following SARS-CoV-2 MA10 infection with a score of 0 indicating unchanged lung color and 4 indicating a darkened and diseased lung. (e) Viral titers in the mice lungs (expressed in plaque forming units per lobe) following challenge.
Figure 1. A single immunization with RBD-NP protects Balb/c cByJ mice from SARS-CoV-2 MA10 challenge. (a–b) Serum neutralizing Ab titers at 2 (a) or 5 (b) weeks post-prime determined using an MLV pseudotyping system; teal squares: 2×0.1 μg group; filled teal circles: 2×1 μg group; open teal circles: 1×1 μg group. (c) Weight loss following SARS-CoV-2 MA10 challenge up to 4 days post infection (N=6). Black, naïve mice; filled teal circles, 2×1 μg group; open teal circles, 1×1 μg group. (d) Congestion score following SARS-CoV-2 MA10 infection with a score of 0 indicating unchanged lung color and 4 indicating a darkened and diseased lung. (e) Viral titers in the mice lungs (expressed in plaque forming units per lobe) following challenge.CC BY-NC-ND · PubMed Central
Figure 2: SARS-CoV-2 RBD-NP vaccination elicits high titers of Abs targeting diverse RBD antigenic sites in NHPs. (a) Vaccination schedules and RBD antigen doses of the different immunogens. (b) Effects of mutations on RBD binding by polyclonal serum Abs, measured by DMS analysis of serum obtained 8 weeks post-prime from a pigtail macaque vaccinated with 12GS-RBD-NP, compared to a previously reported DMS measurement on plasma Ab binding from a representative SARS-CoV-2 human convalescent individual reproduced here for comparison64. The line plots on the left show the summed effect of all mutations at a site in the RBD on sera or plasma binding, with RBD site on the x axis and Ab escape on the y axis. Due to the use of sample-specific FACS gates, the y axes are scaled independently. Sites in the logo plots are colored dark blue if located in the receptor-binding ridge or cyan if located in the RBD 443–450 loop. Larger values indicate more Ab escape. (c–e) Competition ELISA between 0.2 nM human ACE2-Fc (c), 2 nM CR3022 mAb (d), or 0.01 nM S309 mAb (e) and RBD-NP-elicited sera in rhesus/pigtail macaques or HexaPro-elicited sera in rhesus macaques at various time points following vaccination, benchmarked against HCP. Each plot shows the magnitude of inhibition of ACE2/mAb binding to immobilized SARS-CoV-2 S 2P, expressed as reciprocal serum dilution blocking 50% of the maximum binding response.
Figure 2: SARS-CoV-2 RBD-NP vaccination elicits high titers of Abs targeting diverse RBD antigenic sites in NHPs. (a) Vaccination schedules and RBD antigen doses of the different immunogens. (b) Effects of mutations on RBD binding by polyclonal serum Abs, measured by DMS analysis of serum obtained 8 weeks post-prime from a pigtail macaque vaccinated with 12GS-RBD-NP, compared to a previously reported DMS measurement on plasma Ab binding from a representative SARS-CoV-2 human convalescent individual reproduced here for comparison64. The line plots on the left show the summed effect of all mutations at a site in the RBD on sera or plasma binding, with RBD site on the x axis and Ab escape on the y axis. Due to the use of sample-specific FACS gates, the y axes are scaled independently. Sites in the logo plots are colored dark blue if located in the receptor-binding ridge or cyan if located in the RBD 443–450 loop. Larger values indicate more Ab escape. (c–e) Competition ELISA between 0.2 nM human ACE2-Fc (c), 2 nM CR3022 mAb (d), or 0.01 nM S309 mAb (e) and RBD-NP-elicited sera in rhesus/pigtail macaques or HexaPro-elicited sera in rhesus macaques at various time points following vaccination, benchmarked against HCP. Each plot shows the magnitude of inhibition of ACE2/mAb binding to immobilized SARS-CoV-2 S 2P, expressed as reciprocal serum dilution blocking 50% of the maximum binding response.CC BY-NC-ND · PubMed Central
Figure 3. SARS-CoV-2 RBD-NP and HexaPro S elicit Abs with similar neutralization breadth towards SARS-CoV-2 RBD mutants detected in clinical isolates. (a) Neutralizing Ab titers against wildtype (D614G) SARS-CoV-2 S and RBD point mutants determined using SARS-CoV-2 RBD-NP-elicited sera in pigtail macaques (magenta), in rhesus macaques (blue), and HexaPro-elicited sera in rhesus macaques (gray) with an HIV pseudotyping system. (b) Neutralizing Ab titers against HIV pseudotyped viruses harboring wildtype (D614G) SARS-CoV-2 S, B.1.351 S or B.1.1.7 S determined using SARS-CoV-2 RBD-NP-elicited sera in rhesus macaques (blue), HexaPro-elicited sera in rhesus macaques (gray), or plasma from individuals who received two doses of Pfizer mRNA vaccine (open circles). (c) Neutralizing Ab titers against VSV pseudotyped viruses harboring wildtype (D614G) SARS-CoV-2 S, B.1.351 S or B.1.1.7 S determined using SARS-CoV-2 RBD-NP-elicited sera in rhesus macaques (blue) or HexaPro-elicited sera in rhesus macaques (gray). (d) Neutralizing Ab titers against HIV pseudotyped viruses harboring wildtype (D614G) SARS-CoV-2 S, Pangolin-GD S or SARS-CoV S determined using SARS-CoV-2 RBD-NP-elicited sera in pigtail macaques (magenta), in rhesus macaques (blue), or HexaPro-elicited sera in rhesus macaques (gray). (e) Neutralizing Ab titers against VSV pseudotyped viruses harboring wildtype (D614G) SARS-CoV-2 S, Pangolin-GD S, RaTG13 S, SARS-CoV S or WIV1 S determined using SARS-CoV-2 RBD-NP-elicited sera in rhesus macaques (blue) or HexaPro-elicited sera in rhesus macaques (gray).
Figure 3. SARS-CoV-2 RBD-NP and HexaPro S elicit Abs with similar neutralization breadth towards SARS-CoV-2 RBD mutants detected in clinical isolates. (a) Neutralizing Ab titers against wildtype (D614G) SARS-CoV-2 S and RBD point mutants determined using SARS-CoV-2 RBD-NP-elicited sera in pigtail macaques (magenta), in rhesus macaques (blue), and HexaPro-elicited sera in rhesus macaques (gray) with an HIV pseudotyping system. (b) Neutralizing Ab titers against HIV pseudotyped viruses harboring wildtype (D614G) SARS-CoV-2 S, B.1.351 S or B.1.1.7 S determined using SARS-CoV-2 RBD-NP-elicited sera in rhesus macaques (blue), HexaPro-elicited sera in rhesus macaques (gray), or plasma from individuals who received two doses of Pfizer mRNA vaccine (open circles). (c) Neutralizing Ab titers against VSV pseudotyped viruses harboring wildtype (D614G) SARS-CoV-2 S, B.1.351 S or B.1.1.7 S determined using SARS-CoV-2 RBD-NP-elicited sera in rhesus macaques (blue) or HexaPro-elicited sera in rhesus macaques (gray). (d) Neutralizing Ab titers against HIV pseudotyped viruses harboring wildtype (D614G) SARS-CoV-2 S, Pangolin-GD S or SARS-CoV S determined using SARS-CoV-2 RBD-NP-elicited sera in pigtail macaques (magenta), in rhesus macaques (blue), or HexaPro-elicited sera in rhesus macaques (gray). (e) Neutralizing Ab titers against VSV pseudotyped viruses harboring wildtype (D614G) SARS-CoV-2 S, Pangolin-GD S, RaTG13 S, SARS-CoV S or WIV1 S determined using SARS-CoV-2 RBD-NP-elicited sera in rhesus macaques (blue) or HexaPro-elicited sera in rhesus macaques (gray).CC BY-NC-ND · PubMed Central
Figure 4. Mosaic and cocktail RBD-NPs elicit neutralizing Ab against multiple sarbecoviruses and protect against heterotypic challenge in 15 week old Balb/c cByJ mice. a, Schematic of in vitro assembly of mRBD-NP and cRBD-NP. b, Neutralizing Ab titers against wildtype (D614G) SARS-CoV-2 S MLV pseudovirus at week 5 (2 weeks post-boost) elicited by monovalent, mosaic, and cocktail RBD-NPs. c, Neutralizing Ab titers against SARS-CoV S MLV pseudovirus at week 5 (2 weeks post-boost) elicited by monovalent, mosaic, and cocktail RBD-NPs. d, Neutralizing Ab titers against SARS-CoV-2 B.1.351 S MLV pseudovirus at week 5 (2 weeks post-boost) elicited by monovalent, mosaic, and cocktail RBD-NPs. e, Weight loss following SARS-CoV MA15 challenge up to 4 days post infection (N=6). f, Congestion score following SARS-CoV MA15 infection with a score of 0 indicating unchanged lung color and 4 indicating a darkened and diseased lung. g, Viral titers in the mice lungs (expressed in plaque forming units per lobe) following challenge.
Figure 4. Mosaic and cocktail RBD-NPs elicit neutralizing Ab against multiple sarbecoviruses and protect against heterotypic challenge in 15 week old Balb/c cByJ mice. a, Schematic of in vitro assembly of mRBD-NP and cRBD-NP. b, Neutralizing Ab titers against wildtype (D614G) SARS-CoV-2 S MLV pseudovirus at week 5 (2 weeks post-boost) elicited by monovalent, mosaic, and cocktail RBD-NPs. c, Neutralizing Ab titers against SARS-CoV S MLV pseudovirus at week 5 (2 weeks post-boost) elicited by monovalent, mosaic, and cocktail RBD-NPs. d, Neutralizing Ab titers against SARS-CoV-2 B.1.351 S MLV pseudovirus at week 5 (2 weeks post-boost) elicited by monovalent, mosaic, and cocktail RBD-NPs. e, Weight loss following SARS-CoV MA15 challenge up to 4 days post infection (N=6). f, Congestion score following SARS-CoV MA15 infection with a score of 0 indicating unchanged lung color and 4 indicating a darkened and diseased lung. g, Viral titers in the mice lungs (expressed in plaque forming units per lobe) following challenge.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 116 references

Research works printed but not linked: 1

  1. Davies, 2020, Estimated transmissibility and severity of novel SARS-CoV-2 Variant of Concern 202012/01 in England, medRxiv

Cited by

Sorted by citations

Related

See all

Metadata

Authors
Walls, A. C., Miranda, M. C., Schäfer, A., Pham, M. N., Greaney, A., Arunachalam, P. S., Navarro, M.-J., Tortorici, M. A., Rogers, K., O’Connor, M. A., Shirreff, L., Ferrell, D. E., Bowen, J., Brunette, N., Kepl, E., Zepeda, S. K., Starr, T., Hsieh, C.-L., Fiala, B., Wrenn, S., Pettie, D., Sydeman, C., Sprouse, K. R., Johnson, M., Blackstone, A., Ravichandran, R., Ogohara, C., Carter, L., Tilles, S. W., Rappuoli, R., Leist, S. R., Martinez, D. R., Clark, M., Tisch, R., O’Hagan, D. T., Van Der Most, R., Van Voorhis, W. C., Corti, D., McLellan, J. S., Kleanthous, H., Sheahan, T. P., Smith, K. D., Fuller, D. H., Villinger, F., Bloom, J., Pulendran, B., Baric, R. S., King, N. P., & Veesler, D.
Affiliations
  • University of Washington (US)
  • University of North Carolina at Chapel Hill (US)
  • Stanford University (US)
  • Centre National de la Recherche Scientifique (FR)
  • University of Louisiana at Lafayette (US)
  • Fred Hutch Cancer Center (US)
  • The University of Texas at Austin (US)
  • GlaxoSmithKline (Italy) (IT)
  • Vir Biotechnology (Switzerland) (CH)
  • Gates Foundation (US)
Corresponding author
  • King, Neil P.
  • Veesler, David
ORCID
Venue
Cell
Publisher
Elsevier BV
Published
2021-10
Volume
184
Issue
21
Pages
5432-5447.e16
ISSN
0092-8674 (ISSN-L)
DOI
10.1016/j.cell.2021.09.015
PMC
PMC7986998
OpenAlex
W3199882158
Cited by
185
References
116
Citations by year
2026: 15 · 2025: 24 · 2024: 27 · 2023: 35 · 2022: 59 · 2021: 25
FWCI
11.55
Type
journal article
Language
en
Open access
Licence
Locations
  • Cell (publishedVersion, cc-by)
  • bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (submittedVersion, cc-by-nc-nd)
Funders
  • Burroughs Wellcome Fund (U01 AI149644, HHSN272201700036I-75N93020F00001)
  • Howard Hughes Medical Institute
  • Defense Threat Reduction Agency (HDTRA1-18-1-0001)
  • National Institute of General Medical Sciences (R01GM120553)
  • Bill and Melinda Gates Foundation (017592, OPP1156262, INV\u2013017592)
  • Pfizer
  • University of Washington
  • Gilead Sciences
  • GlaxoSmithKline (63/032,502)
  • North Carolina General Assembly
  • National Institute of Allergy and Infectious Diseases (DP1AI158186, F32 AI152296, T32 AI007151, R01-AI127521, 5T32GM008268-32, HHSN272201700059C)
  • Office of Research Infrastructure Programs, National Institutes of Health (P51-OD010425)
Topics
  • Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
  • Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Animal Virus Infections Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
Keywords
Sarbecovirus, SARS-CoV-2, receptor binding domain, nanoparticle vaccine, multivalent vaccine, heterologous protection, neutralizing antibodies, SARS-CoV, spike protein mutations, mosaic vaccine, dose sparing, non-human primates

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review